Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy
- Address
- lock Available on a paid plan
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy - Advanced Immunology and Hematology Research Center
The Dr Jan Biziel University Hospital No. 2 in Bydgoszcz stands as a leading Polish research institution specializing in autoimmune disorders and hematologic malignancies. The center demonstrates extensive expertise across multiple therapeutic domains, with a particular emphasis on complex systemic diseases requiring advanced immunological interventions and novel targeted therapies.
- Rheumatologic and autoimmune diseases including systemic lupus erythematosus, psoriatic arthritis, rheumatoid arthritis, Sjögren's syndrome, and systemic sclerosis
- B-cell malignancies encompassing chronic lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, and marginal zone lymphoma
- Cardiovascular interventions including acute coronary syndrome management, peripheral arterial disease, and acute ischemic stroke treatment
- Specialized care in rare conditions such as primary immune thrombocytopenia, giant cell arteritis, paroxysmal nocturnal hemoglobinuria, and inflammatory myopathies
The hospital's research portfolio reflects significant involvement in Phase 2 and Phase 3 clinical trials evaluating cutting-edge biologic therapies, BTK inhibitors, bispecific antibodies, and novel immunomodulatory agents. The center's participation in comparative effectiveness studies and long-term safety follow-up trials demonstrates its commitment to evidence-based medicine and patient-centered outcomes research across diverse medical specialties including cardiology, neonatology, and vascular interventions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 14 therapeutic areas and 15 of 153 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 145 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 37 by active trials.
- 1Janssen Cilag International5active
lock +36 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International12trials
lock +23 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy
lock Showing 1 of 114 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus | Bristol Myers Squibb International Corporation | Phase II | Not Recruiting | May 2019 | Mar 2025 |
IMP list
lock Showing 1 of 153 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Venetoclax | 8 | Unknown | 2019-03-22 | 2026-05-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.